Figure 3.

Percentage of patients with erythema based on timing of gastrostomy tube placement. A total of 53% (31/58) solid tumor patients developed erythema at their GT site. Fifteen patients with Neuroblastoma developed erythema with 40% (6/15) of these patients having the GT placed prior to treatment start and 60% (9/15) having it placed after treatment start. Five patients with osteosarcoma had erythema with 80% (4/5) of patients having their GT placed prior to treatment start and 20% (1/5) having it placed after treatment start. Five patients with erythema had Ewing sarcoma with 40% (2/5) having their GTs placed prior to start of treatment and 60% (3/5) having it placed after treatment start. Five patients with GT erythema had rhabdomyosarcoma with all 5 (100%) patients having their GT placed after treatment start. One patient with Wilms tumor had a GT placed after treatment start and developed erythema (100%). Lastly, no patients with hepatoblastoma experienced GT erythema.